Prevention of venous thromboembolism in pregnant women with congenital antithrombin deficiency: a retrospective study of a candidate protocol

Int J Hematol. 2022 Jul;116(1):60-70. doi: 10.1007/s12185-022-03327-7. Epub 2022 Mar 22.

Abstract

Background: The best thromboprophylaxis for pregnant women with congenital antithrombin deficiency (CAD) is controversial.

Objective: To clarify the effectiveness of a protocol for venous thromboembolism (VTE) prevention in pregnant women with CAD.

Methods: Women at high risk of VTE were administered antithrombin concentrate and heparin after conception, whereas those at low risk of VTE were administered heparin alone until delivery. All women received antithrombin concentrate at delivery except for one who was diagnosed with CAD.

Results: Ten women had CAD, including one in the high-risk group and nine in the low-risk group. No women had VTE at delivery as per the protocol for VTE prevention. Almost all women had increased antithrombin activity before delivery followed by maintenance at ≥ 70% due to antithrombin concentrate administration. VTE prophylaxis during and after delivery was successful in all women with CAD. However, one woman in the low-risk group did not receive heparin and developed VTE induced by severe hyperemesis at 9 gestational weeks, before the diagnosis of CAD. Women in the high-risk group received antithrombin concentrate after delivery but had increased D-dimer levels at postpartum.

Conclusions: Our protocol to prevent VTE in pregnant women with CAD is safe and effective.

Keywords: Antithrombin concentrate; Caesarean section; Congenital antithrombin deficiency; D-dimer; Heparin; Pregnancy; Thromboprophylaxis; Venous thromboembolism.

MeSH terms

  • Anticoagulants / therapeutic use
  • Antithrombin III
  • Antithrombin III Deficiency* / complications
  • Antithrombin III Deficiency* / drug therapy
  • Antithrombins / therapeutic use
  • Female
  • Heparin / therapeutic use
  • Humans
  • Pregnancy
  • Pregnant People
  • Retrospective Studies
  • Risk Factors
  • Venous Thromboembolism* / etiology
  • Venous Thromboembolism* / prevention & control

Substances

  • Anticoagulants
  • Antithrombins
  • Antithrombin III
  • Heparin